Top Story

Speaker: Withholding antihypertensive medications prior to hemodialysis is unnecessary, harmful

March 6, 2018

FDA approves Relypsa's hyperkalemia drug

October 21, 2015
The U.S. Food and Drug Administration has approved Relypsa, Inc.'s Veltassa (patiromer for oral suspension) to treat hyperkalemia. Veltassa is the first new…

FDA approves treatment combo for pulmonary arterial hypertension

October 5, 2015
The U.S. Food and Drug Administration has approved the use of Letairis (ambrisentan) in combination with tadalafil for the treatment of pulmonary arterial…

Patiromer reduces potassium levels in chronic kidney disease patients with hyperkalemia

September 16, 2015
Patiromer FOS, made by Relypsa Inc., significantly reduced blood potassium from baseline levels in patients with moderate-to-severe hyperkalemia (mean blood…
More Headlines »

Pain Management Update

No commercial support for this activity.

This course is designed to provide healthcare professionals with information on pain including the physiology and types…
More »

Presentation of Renal Disease in Children

Pediatric Annals, March 2013, Volume 42 Issue 3
CME Educational Objectives 1. Review the modes of presentation of renal disease in children. 2. Understand the role of…
More »

HIV Curbside Consults – Volume II: HIV Treatment in Patients with Comorbidities

This activity is supported by an educational grant from ViiV Healthcare.

In this case-based video, Eric S. Daar, MD and Paul E. Sax, MD discuss the management of an older man with long-term…
More »
Meeting News

VIDEO: Social media is a ‘win’ for kidney patients, professionals

March 17, 2018
More »